Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

RGN-259 matches or outpaces approved dry eye treatments
June 2018
SHARING OPTIONS:

PRINCETON, N.J.—The 2018 Association for Research in Vision and Ophthalmology meeting saw ReGenTree LLC, a joint venture between GtreeBNT and RegeneRx Biopharmaceuticals, share results of a comparison study of RGN-259 and marketed products for dry eye syndrome. Treatment with RGN-259 in a mouse model of dry eye was found to promote recovery of mucins and goblet cells, improve corneal integrity, increase tears and reduce inflammation, results that were comparable to or better than those seen from approved treatments such as cyclosporine A (Restasis), lifitegrast (Xiidra) and diquafosol (Diquas). ReGenTree has completed two Phase 3 studies of RGN-259 for dry eye in the United States, ARISE-1 and ARISE-2, and has a Phase 3 study underway in the orphan indication neurotrophic keratopathy.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.